Monte Rosa Therapeutics, Inc.
GLUE- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001826457
In the last 90 days, Monte Rosa Therapeutics, Inc. insiders filed 0 open-market purchases and 3 sales; 192 institutions reported holding it in 13F filings for Q2 2026, worth $2.24B in total; Duquesne Family Office is the only superinvestor holding it.
Q4 2024 vs. Q3 2024
How the institutions holding Monte Rosa Therapeutics, Inc. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Q4 2024 | Change |
|---|---|---|---|
| Holders | 81 | 105 | +24 |
| Shares | 49.8M | 61.0M | +11.2M (+22.6%) |
| Value | $263.7M | $423.3M | +$159.6M (+60.5%) |
New holders (35)
Institutions that held Monte Rosa Therapeutics, Inc. at the end of Q4 2024 but not at the end of Q3 2024.
Sold out (11)
Institutions that held Monte Rosa Therapeutics, Inc. at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| ExodusPoint Capital Management, LP | 393,586 | $2.09M |
| Sphera Funds Management Ltd. | 118,103 | $625.9K |
| Acadian Asset Management LLC | 110,835 | $586.0K |
| HRT Financial LP | 38,911 | $206.0K |
| EntryPoint Capital, LLC | 33,219 | $176.1K |
| Bridgeway Capital Management, LLC | 25,000 | $132.5K |
| UBS Asset Management Americas Inc | 24,100 | $127.7K |
| Cornercap Investment Counsel Inc | 19,236 | $102.0K |
| Meeder Asset Management Inc | 10,050 | $53.3K |
| STRS Ohio | 3,100 | $16.4K |
| Capital Performance Advisors LLP | 29 | $154 |